A study from the University of Copenhagen, published in Blood, provides new evidence that Staphylococcus aureus and its toxins can induce drug resistance in malignant T cells against therapies commonly used in cutaneous T-cell lymphoma (CTCL), including HDAC inhibitors and chemotherapies.
Importantly, the study showed that selective bacterial killing using a MICREOS engineered, S. aureus-targeting endolysin countered this drug-resistance effect.
These findings further support the potential of engineered endolysins as a novel therapeutic modality in CTCL and highlight the opportunity for precision biologics to address pathogen-driven mechanisms of disease progression and treatment resistance.
https://isim.ku.dk/news-from-isim/2024/germs-can-offset-the-effect-of-cancer-therapy
No responses yet